JP2021521171A5 - - Google Patents
Info
- Publication number
- JP2021521171A5 JP2021521171A5 JP2020555466A JP2020555466A JP2021521171A5 JP 2021521171 A5 JP2021521171 A5 JP 2021521171A5 JP 2020555466 A JP2020555466 A JP 2020555466A JP 2020555466 A JP2020555466 A JP 2020555466A JP 2021521171 A5 JP2021521171 A5 JP 2021521171A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- sugar
- preparation according
- item
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201841013647 | 2018-04-10 | ||
| IN201841013647 | 2018-04-10 | ||
| PCT/IN2019/050293 WO2019198101A1 (en) | 2018-04-10 | 2019-04-10 | Stable formulations of therapeutic antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021521171A JP2021521171A (ja) | 2021-08-26 |
| JP2021521171A5 true JP2021521171A5 (enExample) | 2022-04-15 |
Family
ID=68164106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555466A Pending JP2021521171A (ja) | 2018-04-10 | 2019-04-10 | 治療用抗体の安定な製剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12433947B2 (enExample) |
| EP (1) | EP3773696A4 (enExample) |
| JP (1) | JP2021521171A (enExample) |
| CN (1) | CN112292146A (enExample) |
| AU (1) | AU2019251453A1 (enExample) |
| BR (1) | BR112020020703A2 (enExample) |
| CO (1) | CO2020013571A2 (enExample) |
| SG (1) | SG11202009876TA (enExample) |
| WO (1) | WO2019198101A1 (enExample) |
| ZA (1) | ZA202006264B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202012778YA (en) | 2015-12-18 | 2021-01-28 | Astellas Pharma Inc | Pharmaceutical composition comprising anti-human tslp receptor antibody |
| WO2019198099A1 (en) * | 2018-04-10 | 2019-10-17 | Dr. Reddy's Laboratories Limited | Stable antibody formulation |
| WO2024098180A1 (en) * | 2022-11-07 | 2024-05-16 | Wuxi Biologics (Hong Kong) Limited | Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same |
| EP4259192A4 (en) * | 2020-12-09 | 2024-11-20 | Dr. Reddy's Laboratories Limited | STABLE AQUEOUS BUFFER-FREE FORMULATION OF AN INTEGRIN ANTIBODY |
| EP4346899A1 (en) * | 2021-06-04 | 2024-04-10 | Polpharma Biologics S.A. | Vedolizumab formulation |
| EP4717712A2 (en) * | 2021-12-27 | 2026-04-01 | Polpharma Biologics S.A. | Vedolizumab formulation |
| TW202432601A (zh) | 2022-11-07 | 2024-08-16 | 美商上游生物公司 | 包含抗人類ｔｓｌｐ受體抗體之醫藥組成物及其使用方法 |
| WO2024249568A1 (en) | 2023-05-30 | 2024-12-05 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| CN121889424A (zh) | 2023-08-14 | 2026-04-17 | 派拉冈医疗公司 | α4β7整联蛋白结合蛋白及使用方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2236154T3 (en) | 2003-02-10 | 2018-06-25 | Biogen Ma Inc | IMMUNOGLOBULIN INFORMATION AND METHOD OF PREPARING IT |
| NZ595526A (en) * | 2007-06-14 | 2013-03-28 | Biogen Idec Inc | Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant |
| US20090208492A1 (en) * | 2007-06-14 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
| BRPI0820819B1 (pt) * | 2007-12-21 | 2021-06-08 | F. Hoffmann-La Roche Ag | formulação de anticorpos humanizados b-ly 1 e seu uso |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| MX367097B (es) * | 2011-05-02 | 2019-08-05 | Millennium Pharm Inc | FORMULACION PARA ANTICUERPO ANTI-A4ß7. |
| TWI752912B (zh) | 2015-07-17 | 2022-01-21 | 美商寇西勒斯生物科技股份有限公司 | 那他珠單抗的穩定水性調配物 |
| CN114375307B (zh) | 2019-06-10 | 2025-12-05 | 武田药品工业株式会社 | 产生抗α4β7抗体的方法 |
-
2019
- 2019-04-10 US US17/045,406 patent/US12433947B2/en active Active
- 2019-04-10 SG SG11202009876TA patent/SG11202009876TA/en unknown
- 2019-04-10 JP JP2020555466A patent/JP2021521171A/ja active Pending
- 2019-04-10 BR BR112020020703-9A patent/BR112020020703A2/pt not_active IP Right Cessation
- 2019-04-10 AU AU2019251453A patent/AU2019251453A1/en not_active Abandoned
- 2019-04-10 EP EP19785714.7A patent/EP3773696A4/en active Pending
- 2019-04-10 CN CN201980038006.9A patent/CN112292146A/zh active Pending
- 2019-04-10 WO PCT/IN2019/050293 patent/WO2019198101A1/en not_active Ceased
-
2020
- 2020-10-08 ZA ZA2020/06264A patent/ZA202006264B/en unknown
- 2020-10-28 CO CONC2020/0013571A patent/CO2020013571A2/es unknown